ArticleFuture medicinal chemistry2026
Rational design and biological investigation of benzylidene-substituted pyrazolo[3,4-
Article in Future medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPIM-1 kinase is a significant oncogenic serine/threonine kinase that is implicated in various aspects of cancer cell proliferation, survival, and tumor progression. In this manuscript, a novel series of benzylidene-substituted pyrazolo[3,4-
methodsThe novel derivatives were synthesized by a novel synthetic route involving a three-step synthetic method from 2-chloro-3-cyanopyridine to produce a total of ten derivatives 6A-6J. The structures of the novel derivatives were confirmed by Fourier Transform Infrared Spectroscopy (FT-IR), 1H and 13C Nuclear Magnetic Resonance Spectroscopy (NMR), and Mass Spectroscopy. The anticancer activity of the novel derivatives was assessed by evaluating their inhibitory activity against the MCF-7 human breast cancer cell line by a colorimetric MTT assay. The inhibitory activity of the novel derivatives against PIM-1 kinase was assessed by an enzyme-linked immunosorbent assay. The binding mode of the most active derivatives within the PIM-1 kinase active site was assessed by molecular docking studies.
resultsThe results from this investigation revealed that some of the novel derivatives exhibited significant anticancer activity against the MCF-7 human breast cancer cell line. The most potent derivative 6H had an IC₅₀ value of 1.43 ± 0.18 μM, while compound 6D had an IC₅₀ value of 1.56 ± 0.30 μM compared to the standard drug doxorubicin. The inhibitory activity of the most active derivatives against PIM-1 kinase was concentration-dependent. The results from the molecular docking studies revealed that compound 6H had a favorable binding mode within the PIM-1 kinase active site by hydrogen bonding and hydrophobic interactions with some amino acid residues within the enzyme's active site.
conclusionThe results from this investigation revealed that benzylidene-substituted pyrazolo[3,4-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.